A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

The global Diabetes Drugs Market size was valued at USD 84.65 billion in 2024 and is expected to be worth around USD 177.74 ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.

Groundbreaking research reveals how common diabetes medications might offer unprecedented protection against heart attacks ...

"This may inform prescribing of glucose-lowering medications among patients with T2D and active COPD," making SGLT2 and GLP-1 drugs preferable over DPP-4 inhibitors for these patients, the group ...

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Experts are now calling for NHS guidance - which does not recommend managing diabetes with different drugs depending on age - ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

SGLT-2 inhibitors, compared with DPP-4 inhibitors ... To assess the effect of these drugs, compared with DPP-4 inhibitors, on the risk for cirrhosis and other severe liver complications ...